IAS – the International AIDS Society – calls for people living with HIV to be included in priority populations for COVID-19 vaccine rollout

New studies to be presented at IAS 2021 – the 11th IAS Conference on HIV Science – show important progress in HIV prevention, treatment and cure efforts despite major disruption to HIV programmes and research during the COVID-19 pandemic.

Several studies spotlight the intersection of the HIV and COVID-19 pandemics, including new evidence from a large-scale World Health Organization (WHO) analysis that HIV is a significant independent risk factor for severe COVID-19 illness at hospitalization and in-hospital death. There is also evidence from Uganda that women face increased risk of gender-based violence and HIV during COVID-19 lockdowns.

Convened by IAS – the International AIDS Society – the virtual conference will expect around 6000 participants from 18-21 July. The conference officially opens Sunday with remarks from speakers including German Chancellor Angela Merkel; and a panel discussion on the COVID-19 and HIV pandemics with global health experts including Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases.

The IAS featured five studies at a press conference held today to preview scientific highlights for media.

WHO report finds HIV infection is an independent risk factor for severe COVID-19 illness

A new global analysis and  from WHO concludes that HIV infection is a significant independent risk factor for both severe illness at hospital admission and in-hospital mortality.

Informed by these findings, the IAS called on countries to add people living with HIV to the list of groups prioritized in vaccine rollout efforts.

“This study underscores the importance of countries including all people living with HIV in the list of priority populations for national COVID-19 vaccine programmes,” IAS President and IAS 2021 International Co-Chair Adeeba Kamarulzaman said. “The global community must also do much more to bring COVID-19 vaccines to countries around the world with high prevalence of HIV and other diseases. It is unacceptable that as of today, less than 3% of the entire African continent has received a single dose of the vaccine and less than 1.5% have received both doses.”

Previous evidence regarding the impact of HIV infection on the severity and mortality of COVID-19 has been limited and sometimes conflicting, and most analyses have been based on relatively small cohorts of individuals in specific settings. In this report, WHO researchers analysed clinical data submitted to the WHO Global Clinical Platform for COVID-19 from 24 countries on more than 15,500 people living with HIV who were hospitalized for COVID-19.

The mean age of these patients was 45.5 years. About 37% were male, about 92% had received antiretroviral therapy and about 36% had severe or critical COVID-19 illness on admission. Their most common underlying chronic conditions were hypertension, diabetes and obesity. Among patients with a known outcome, 23% died in hospital. The study team determined that HIV infection was associated with an increased risk of severe or critical COVID-19 presentation (aOR 1.13, 95% CI: 1.09–1.17), after adjusting for age, sex and comorbidity burden, and of in-hospital mortality (aHR 1.30, 95% CI: 1.24–1.36) after adjusting by age, gender, disease severity and comorbidities burden.

Abstract and session: Clinical characteristics and prognostic factors in people living with HIV hospitalized with COVID-19: findings from the WHO Global Clinical Platform (2605, Track B)


Improved strategy to treat highly drug-resistant TB

Positive results from ZeNix, a Phase 3 trial seeking to improve a key treatment strategy for highly drug-resistant tuberculosis (TB), could lead to changes in TB treatment guidelines and have real benefits for people living with TB.The study enrolled 181 people with highly drug-resistant TB in South Africa, Russia, Georgia, and Moldova. They were treated for six months with daily bedaquiline and pretomanid, and daily linezolid (a combined regimen known as BPaL) starting at 1,200mg for either six or two months or 600mg for either six or two months.

A high relapse-free cure rate was observed in all four study arms. In addition, people who received reduced doses and/or shorter durations of linezolid were less likely to experience adverse events of peripheral neuropathy and myelosuppression. They were also less likely to require linezolid dose modification. According to the study team, these results confirm the high relapse-free cure rate for the BPaL regimen in highly drug-resistant TB and suggest that reduced doses and/or shorter durations of linezolid than 1,200 mg for six months have similar efficacy and improved safety.

“This month, we will mark 100 years since the BCG vaccine for tuberculosis was first administered. This vaccine has saved many lives – but unfortunately, it has very limited effectiveness and it is still the only TB vaccine we have,” IAS 2021 Local Co-Chair Hendrik Streeck, the Director of the Institute of Virology and Professor of HIV Research at the University of Bonn in Germany, said. “This anniversary is a reminder of the urgent need for improved prevention and treatment options, including for highly drug-resistant TB.”

Abstract and session: High rate of successful outcomes treating highly resistant TB in the ZeNix study of pretomanid, bedaquiline and alternative doses and durations of linezolid (Abstract 2405, Track B)  

Prevalence of HIV drug resistance in PrEP rollout participants who acquire HIV

Note: The following summary of Abstract 2585 has been updated 16 July 2021 to include new data and information from the author.

A study from the Global Evaluation of Microbicide Sensitivity (GEMS) project found very low rates of seroconversion among individuals participating in HIV pre-exposure prophylaxis (PrEP) rollout programmes in sub-Saharan Africa. In the small subset of individuals who acquired HIV despite being in a PrEP programme, 23% were found to have HIV with resistance mutations to the antiretroviral drugs used for PrEP.

The project implemented drug resistance monitoring for PrEP users who were diagnosed with HIV during participation in oral TDF-based PrEP programmes in Eswatini, Kenya, South Africa and Zimbabwe. Of the estimated 104,000 PrEP users, 229 seroconversions were reported and 208 participants provided a sample for the study. Half of participants were 16-24 years of age and three-quarters were female. The majority were on PrEP from more than three months before becoming HIV positive.

Of the 118 samples successfully genotyped, 44% had at least one HIV drug resistance mutation. Most of the resistance mutations were unrelated to PrEP use; that is, they had originated from antiretroviral therapy in the partner who transmitted HIV. Only one-fifth of the samples had mutations associated with the drugs used for PrEP, with the majority (23 of 27 cases) due to the emtricitabine/FTC mutation, M184I/V. There were only four cases of tenofovir-resistant HIV. Fortunately, recent studies have shown that HIV with the M184V/I mutations and/or tenofovir-associated mutations can be effectively treated with widely available combinations of antiretroviral drugs that are in the form of one pill taken daily.

“Taking PrEP every day is very effective at preventing HIV,” Dr Urvi Parikh, Associate Professor of Medicine at the University of Pittsburgh and Co-Director of the GEMS study, said. “The number of reported infections on PrEP was very small compared to the number of PrEP users, which tells us that the benefit of PrEP in preventing HIV far outweighs the risk of drug resistance.” Continued monitoring for drug resistance with PrEP rollout will be important for the long-term success of both treatment and prevention programmes.

Abstract and session: High Rates of Drug Resistance in Individuals Diagnosed with HIV in Tenofovir Disoproxil Fumarate (TDF)-Based Pre-Exposure Prophylaxis Rollout Programs in Kenya, Zimbabwe, Eswatini and South Africa (2585, Track C)


Promising adherence to oral PrEP and the dapivirine vaginal ring

Interim results from the REACH HIV prevention study show encouraging levels of adherence to both the dapivirine vaginal ring and oral PrEP among adolescent girls and young women in Africa. The study assessed safety, adherence and acceptability of both products among adolescent girls and young women.

The study enrolled nearly 250 HIV-negative, non-pregnant young women aged 16 to 21 years from South Africa, Uganda and Zimbabwe. Participants were randomized to either the monthly dapivirine ring or daily oral PrEP for six months and then switched to the second product for six months. Most participants had at least moderate adherence to the ring and oral PrEP. High adherence was observed in about half of the ring users and about 22% of oral PrEP users. Adverse events of Grade 2 or higher were experienced by 78% of ring users and 77% of oral PrEP users.

Acceptability varied, with about 88% liking the ring and about 64% liking oral PrEP. Only one HIV acquisition was reported among study participants. The study team concluded that adherence to the dapivirine ring and oral PrEP was higher than previously observed among African adolescent girls and young women. Both products were well tolerated and highly acceptable.

“Adolescent girls and young women account for most of the new HIV infections in sub-Saharan Africa. These findings should accelerate efforts to make these two prevention options available to all those who can benefit,” Prof Kamarulzaman said.

Abstract and session: Adherence to the dapivirine vaginal ring and oral PrEP among adolescent girls and young women in Africa: interim results from the REACH study (2487, Track C)

Sexual violence and HIV exposure during Uganda’s COVID-19 lockdown

Striking results from a large study in Uganda show that sexual violence reports and HIV exposure increased among females during the country’s COVID-19 restrictions.

Researchers analysed routine programme data from the Uganda Health Management System and the Uganda Child Helpline to correlate COVID-19 restrictions with gender-based violence reports, uptake of HIV post-exposure prophylaxis (PEP) and teen pregnancy among Ugandan females. They compared data from two time periods: the six months prior to COVID-19, starting in October 2019; and the first six months of COVID-19 restrictions, starting in April 2020.

They found that among women of all ages, during the first six months of COVID-19 restrictions, there was a 24% increase in post-rape reports and an 18% reduction in PEP uptake compared with the pre-COVID-19 period. More than half of those who reported for post-rape care after the recommended 72-hour intervention timeframe cited lockdown restrictions as the main reason for coming late.

The study team also found that among Ugandan girls, the odds of reporting sexual violence during the COVID-19 period was 1.3 times higher than in the pre-COVID-19 period. There was also a 17% increase in teen pregnancy between the two periods, but that was not found to be statistically significant. The research team concluded that investment in unhindered, flexible and adaptable gender-based violence mitigation is important during pandemics.

“There has been a lot of concern about the potential for COVID-19 lockdowns to fuel what UN Women has called the ‘shadow pandemic’ of increased gender-based violence and unintended pregnancy. This study confirms that HIV risk is also a major concern that should be taken into account when designing pandemic response plans,” Prof Kamarulzaman said.

Abstract and session: Gender-based violence shadows COVID-19: Increased sexual violence, HIV exposure and teen pregnancy among girls and women in Uganda (2172, Track D)

Note: Press summaries are based on abstracts; final data presented at the conference may change.

Also timed with the conference, the IAS released the latest episode of its new limited series podcast, HIV unmuted, which marks the 40th anniversary of the first reports of AIDS and recounts the progress made over the past four decades of the global response.


# # #

The IAS Conference on HIV Science is the world’s most influential meeting on HIV research. This biennial conference presents the latest advances in basic, clinical and operational HIV research and facilitates the critical discussions needed to move science into policy and practice. Through its open and inclusive programme featuring diverse and cutting-edge HIV research, the meeting sets the gold standard in HIV convenings. For more information on IAS 2021 – the 11th IAS Conference on HIV Science – visit https://www.ias2021.org.


IAS – the International AIDS Society – leads collective action on every front of the global HIV response through its membership base, scientific authority and convening power. Founded in 1988, the IAS is the world’s largest association of HIV professionals, with members in more than 170 countries. Working with its members, the IAS advocates and drives urgent action to reduce the impact of HIV. The IAS is also the steward of the world’s most prestigious HIV conferences: the International AIDS Conference, the IAS Conference on HIV Science, and the HIV Research for Prevention Conference. In light of the SARS-CoV-2 pandemic, the IAS also convened two abstract-driven COVID-19 conferences, in July 2020 and February 2021.